CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...